# Procyrion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/procyrion

- Industry: Medical Devices & Equipment
- Headquarters: Houston, US
- Website: www.procyrion.com
- Total disclosed funding: $77M
- Latest round: Series E (Dec 13, 2023)
- Investors on record: 4

## About

Procyrion, Inc. is a US-based medical technology company dedicated to developing innovative devices for heart failure treatment, notably the Aortix™ system designed to assist patients with acute decompensated heart failure.Procyrion, Inc. focuses on advancing medical devices for heart failure treatment. Founded in 2005 and headquartered in Houston, Texas, the company has secured funding through various rounds, with its most recent Series E round completed in December 2023, raising USD 57.671 mn from lead investor Fannin Innovation Studio and returning investor BlueBird Ventures. Eric Fain serves as CEO.Procyrion™ specializes in developing advanced medical devices for heart failure, with its flagship product being the Aortix™ percutaneous mechanical circulatory support (pMCS) system. This device enhances blood flow and alleviates symptoms for patients suffering from acute decompensated heart failure. It is particularly targeted at hospitals and healthcare providers in North America and Europe, where the prevalence of heart failure is high. Procyrion's innovative approach has earned it recognition as a Fierce15 Medtech company, solidifying its presence in the medical technology sector.Procyrion generates revenue through direct sales of its Aortix™ device to healthcare institutions involved in heart failure treatment. The business model emphasizes bulk orders to ensure adequate supply for hospitals and clinics, leveraging partnerships with cardiologists who advocate for the device's clinical application. The pricing structure is consistent with industry standards for advanced medical devices, reflecting its innovative technology and clinical significance for cardiac health.In December 2023, Procyrion, Inc. raised USD 57.67 mn in a Series E funding round to support the DRAIN-HF pivotal IDE trial, which evaluates the Aortix device in patients with acute decompensated heart failure. The funding will also enhance product manufacturability and prepare for commercialization. Procyrion aims to expand its reach into new markets and geographic regions, specifically targeting additional healthcare facilities in North America and Europe.

## Funding rounds

- Series E, Dec 13, 2023, $58M — Fannin, BlueBird Ventures
- Series C, Jan 30, 2018, $16M — Fannin, Science Health Development
- Series A, Jun 1, 2012, $3.5M — Texas Emerging Technology Fund, Fannin

## Investors

- Texas Emerging Technology Fund — Series A
- Fannin (https://capitalatlas.ai/funds/fannin) — Series A, Series C, Series E
- Science Health Development — Series C
- BlueBird Ventures (https://capitalatlas.ai/funds/bluebird-ventures) — Series E